LEGN Legend Biotech Corp
Price (delayed)
$33.24
Market cap
$6.1B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.96
Enterprise value
$5.33B
legend biotech corporation is an emerging company focusing on the development of the best-in-class immunotherapy technology for cancer cure. teamed up with outstanding immunologists and molecular biologists, legend has generated
Highlights
The gross profit has soared by 179% YoY and by 20% from the previous quarter
The revenue has surged by 120% year-on-year and by 21% since the previous quarter
The quick ratio has contracted by 37% YoY and by 9% from the previous quarter
The equity is down by 17% YoY and by 7% from the previous quarter
Key stats
What are the main financial stats of LEGN
Market
Valuations
Earnings
Shares outstanding
183.45M
Market cap
$6.1B
Enterprise value
$5.33B
Price to earnings (P/E)
N/A
Price to book (P/B)
5.86
Price to sales (P/S)
9.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.49
Revenue
$627.24M
Gross profit
$392.66M
Operating income
-$136.48M
Net income
-$177.03M
EBIT
-$136.52M
EBITDA
-$113.16M
Free cash flow
-$144.03M
Per share
Balance sheet
Liquidity
EPS
-$0.96
EPS diluted
-$0.96
Free cash flow per share
-$0.79
Book value per share
$5.67
Revenue per share
$3.43
TBVPS
$9.12
Total assets
$1.67B
Total liabilities
$629.61M
Debt
$350.6M
Equity
$1.04B
Working capital
$1.01B
Debt to equity
0.34
Current ratio
4.62
Quick ratio
4.07
Net debt/EBITDA
6.82
Margins
Efficiency
Dividend
EBITDA margin
-18%
Gross margin
62.6%
Net margin
-28.2%
Operating margin
-21.8%
Return on assets
-10.1%
Return on equity
-15.8%
Return on invested capital
-21.8%
Return on capital employed
-9.8%
Return on sales
-21.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LEGN stock price
How has the Legend Biotech stock price performed over time
Intraday
5.46%
1 week
-4.12%
1 month
-5.06%
1 year
-41.1%
YTD
2.15%
QTD
-2.03%
Financial performance
How have Legend Biotech's revenue and profit performed over time
Revenue
$627.24M
Gross profit
$392.66M
Operating income
-$136.48M
Net income
-$177.03M
Gross margin
62.6%
Net margin
-28.2%
The gross profit has soared by 179% YoY and by 20% from the previous quarter
The revenue has surged by 120% year-on-year and by 21% since the previous quarter
The operating margin has soared by 84% YoY and by 60% QoQ
Legend Biotech's net margin has surged by 84% YoY and by 58% QoQ
Growth
What is Legend Biotech's growth rate over time
Valuation
What is Legend Biotech stock price valuation
P/E
N/A
P/B
5.86
P/S
9.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.49
The EPS has surged by 67% year-on-year and by 50% since the previous quarter
The stock's price to book (P/B) is 54% less than its 5-year quarterly average of 12.1 and 25% less than its last 4 quarters average of 7.4
The equity is down by 17% YoY and by 7% from the previous quarter
The revenue has surged by 120% year-on-year and by 21% since the previous quarter
The P/S is 84% less than the 5-year quarterly average of 57.7 and 50% less than the last 4 quarters average of 18.5
Efficiency
How efficient is Legend Biotech business performance
The return on sales has surged by 88% year-on-year and by 65% since the previous quarter
LEGN's return on invested capital has surged by 70% year-on-year and by 57% since the previous quarter
LEGN's return on assets has surged by 67% year-on-year and by 48% since the previous quarter
The company's return on equity has surged by 65% YoY and by 47% QoQ
Dividends
What is LEGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LEGN.
Financial health
How did Legend Biotech financials performed over time
Legend Biotech's total assets is 165% more than its total liabilities
The quick ratio has contracted by 37% YoY and by 9% from the previous quarter
Legend Biotech's current ratio has decreased by 33% YoY and by 7% QoQ
Legend Biotech's debt is 66% lower than its equity
The debt to equity has grown by 31% YoY and by 10% from the previous quarter
The equity is down by 17% YoY and by 7% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.